Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
Patients with a BRCA-related malignancy and/or:
- Patients without a known BRCA mutation must have a probability of harboring a BRCA gene mutation as assessed by BRCAPRO computer program
- Patients with a probability of having genetic mutation ≥ 20% or a BRCA mutation based on a non-Myriad test, must have a formal BRCA testing by Myriad Genetic Laboratories
- Patients with known deleterious BRCA 1 or 2 mutation or a mutation of uncertain significance
Patients who refuse BRCA testing not allowed unless they have another acceptable histology
- First- or second-line metastatic colorectal cancer
- Any-line metastatic mucinous ovarian cancer
- Any line of other metastatic gastrointestinal malignancies in which oxaliplatin has shown some activity (i.e., gastric or pancreatic adenocarcinoma)
May have brain metastases that have been treated and stable for 2 months
Type of study:
Patients receive oral veliparib twice daily and oral capecitabine twice daily on 1-7 and 15-21, and oxaliplatin IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
University of Wisconsin Hospital and Clinics
Contact: George Wilding 608-263-3961 email@example.com
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.